John Lechleiter, Eli Lilly & Co.

Chairman, CEO and President, Eli Lilly & Co.
Total 2014 Compensation: $14.48 million

Eli Lilly & Co. ($LLY) has been hunkered down over the past few lean years, and CEO John Lechleiter participated by forgoing any salary increases. Last year, he and the rest of Lilly took a hit to bonus pay, too. But thanks to some pension accounting, Lechleiter's 2014 total still increased by $3 million over 2013.

Here's how that adds up: Lechleiter's base salary held steady at $1.5 million. His stock awards also stood firm, at $6.75 million. His cash incentive pay slipped by more than one-third--to $1.8 million from $2.9 million. Total? $10.125 million, more than $1 million less than 2013's total.

But the value of Lechleiter's pension and deferred compensation grew by more than $4 million for 2014, bringing the full package to $14.5 million. In 2013, Lilly didn't account for any pension growth in Lechleiter's total.

The number could grow again next year, if things go well. According to Lilly's proxy statement, the pay freeze has ended, and bonuses returned to full strength as of Jan. 1.

For more:
Eli Lilly scores a multibillion-dollar win in Alimta's EU patent fight
Lechleiter takes up Big Pharma's torch to 'debunk' negative myths
Pharma hikes prices on all sorts of meds, but hit diabetes hardest: Bloomberg
Eli Lilly can thank Novartis--and low expectations--for its Q1 earnings beat
Lilly execs take $3M hit to 2014 bonuses, but the pay freeze thaws for 2015
Lilly leans on diabetes, Cyramza in predictions for 2015 growth
Eli Lilly CEO's pay package slides 11% to $14.6M

John Lechleiter, Eli Lilly & Co.

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.